Ocumension Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Ocumension Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 50.6%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 5.7%. De inkomsten zijn gegroeid met een gemiddelde van 61.3% per jaar.

Belangrijke informatie

50.6%

Groei van de winst

92.5%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	5.6%
Inkomstengroei	61.3%
Rendement op eigen vermogen	-11.7%
Nettomarge	-104.0%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Opbrengsten en kosten

Hoe Ocumension Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:1477 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	310	-323	409	109
31 Mar 24	278	-351	416	117
31 Dec 23	246	-380	423	124
30 Sep 23	227	-399	429	141
30 Jun 23	208	-418	435	159
31 Mar 23	184	-411	405	172
31 Dec 22	159	-403	374	184
30 Sep 22	124	-393	340	180
30 Jun 22	90	-383	305	175
31 Mar 22	73	-322	279	172
31 Dec 21	56	-260	254	169
30 Sep 21	44	-426	237	194
30 Jun 21	32	-593	220	220
31 Mar 21	23	-1,429	252	200
31 Dec 20	13	-2,265	284	180
30 Sep 20	8	-2,540	242	150
30 Jun 20	2	-2,816	200	121
31 Mar 20	1	-2,064	130	110
31 Dec 19	0	-1,312	60	99

Kwaliteitswinsten: 1477 is momenteel verliesgevend.

Groeiende winstmarge: 1477 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 1477 is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 50.6% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 1477 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 1477 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 9.4% ).

Rendement op eigen vermogen

Hoge ROE: 1477 heeft een negatief Return on Equity ( -11.66% ), omdat het momenteel verliesgevend is.

Ocumension Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

Consensus forecasts updated

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China